Study explorer (study characteristics and results) method abbreviations pdf   xlsx

display ongoing studies
Study Ref. Design studied treatmentcontrol treatmentpatientsstudy risk of biassample sizes Results

COVID 19 hospitalized meta-analysis

Nouri-Vaskeh
  IRCT20180802040678N4		 RCTangiotensin receptor blockers (ARBs)calcium channel blockerCOVID 19 hospitalizedsome concern
41/41 inconclusive
  • inconclusive 65 % decrease in deaths (PE) with a moderate degree of certainty due to some concern in risk of bias
Duarte
  NCT04355936		 RCTangiotensin receptor blockers (ARBs)standard of careCOVID 19 hospitalizedhigh
41/41 suggested
  • suggested 1.2-fold increase in hospital discharge but with a low degree of certainty due to high risk of bias
REPLACE
  NCT04338009		 RCTdiscontinuation of ACEI/ARBcontinuation of ACEI/ARBCOVID 19 hospitalizedNA
77/75 inconclusive

    COVID-19 mild to moderate meta-analysis

    Lopes (BRACE CORONA)
          NCT04364893    		 RCTdiscontinuation of ACEI/ARBcontinuation of ACEI/ARBCOVID-19 mild to moderatesome concern
    		371/369 inconclusive
      7 studies excluded by filtering options (0 RCT / 7 OBS)

      PE: primary endpoint; (a): to be demonstrated a result must be statistically significant on a primary endpoint (with multiplicity adjustment if necessary);
      Study risk of bias assessed for the study primary endpoint(s) or the main endpoints in case of no formally defined primary endpoint(s).

       

      - About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy - Licence Creative Commons